COVID-19 is a disease caused by infection with SARS-CoV-2, a strain of coronavirus. Respiratory illness is the most common symptom associated with COVID-19 with a severity ranging from mild disease to life-threatening acute respiratory distress syndrome. Patients with advanced age, comorbidities such as obesity, diabetes and cardiovascular disease, or an immunocompromised state are at increased risk for poor outcomes. COVID-19 was declared a pandemic by the World Health Organization (WHO) in 2020. According to the WHO, as at 18 June 2021, more than 177 million people have been infected and COVID-19 has caused more than 3.8 million deaths.

COVID-19 infects humans via the mouth and nasal cavity where it replicates and then progresses into the airways and lungs. The most common symptoms of COVID-19 are fever, dry cough and fatigue, and less common symptoms include soreness of body and throat, diarrhoea, headache, and reduced smell and taste. With more severe cases comes loss/shortness of breath, chest pain, and potentially loss of speech or movement. It typically takes five to six days from infection until the symptoms show.



PROTECT-V is a clinical platform trial that aims to enroll patients at particularly high risk of COVID-19 and its complications. Approximately 1,500 participants will be randomized to active treatment or placebo. The clinical trial in ongoing and is conducted by Cambridge University Hospital Identifier: NCT04870333



UNION's Phase 1 results in Lancet publication:

UNION’s article on dynamics of SARS-CoV-2 in COVID-19 in EBioMedicine, a subjournal of The Lancet: Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.


Back to Pipeline